BioMarin Pharmaceuticals BMRN Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's other non-current liabilities?
- BioMarin Pharmaceuticals (BMRN) reported other non-current liabilities of $155.48M in Q1 2026.
- How has BioMarin Pharmaceuticals's other non-current liabilities changed year-over-year?
- BioMarin Pharmaceuticals's other non-current liabilities increased by 19.9% year-over-year, from $129.69M to $155.48M.
- What is the long-term trend for BioMarin Pharmaceuticals's other non-current liabilities?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's other non-current liabilities has grown at a 5.7% compound annual growth rate (CAGR), from $114.2M to $150.82M.
- What does other non-current liabilities mean?
- Miscellaneous long-term debts or obligations not classified elsewhere.
- How do you interpret other non-current liabilities?
- Unexpected increases may indicate rising long-term risks or changes in accounting estimates for long-term commitments.
- How does other non-current liabilities compare across companies?
- Varies by company; usually represents a small portion of the total liability structure.